BEIGF - BeOne Medicines Ltd. Non-GAAP EPS of ADS2.25, revenue of ADS1.3B
2025-08-06 07:58:19 ET
More on BeiGene
- BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field
- BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit
- BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance
- BeiGene Q2 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on BeiGene